本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

ADC Therapeutics SA

4.18
-0.1150-2.68%
成交量:12.50万
成交额:52.58万
市值:4.68亿
市盈率:-2.65
高:4.31
开:4.25
低:4.17
收:4.29
52周最高:4.74
52周最低:1.05
股本:1.12亿
流通股本:9,224.08万
量比:1.00
换手率:0.14%
股息:- -
股息率:- -
每股收益(TTM):-1.5758
每股收益(LYR):-1.6246
净资产收益率:-705.53%
总资产收益率:-22.99%
市净率:-2.35
市盈率(LYR):-2.57

数据加载中...

2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/13

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/12

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/24

重要事件披露

Form 8-K - Current report
2024/01/19

重要事件披露

Form 8-K - Current report
2024/01/04

重要事件披露

Form 8-K - Current report
2024/01/04

重要事件披露

Form 8-K - Current report
2023/12/19

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/12/05

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/04/28

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/04/17

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/03/21

SEC问询函

CORRESP [Cover] - Correspondence
2023/03/16

SEC问询函

Form CORRESP - Correspondence
2023/03/15

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2023/03/15

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/02/10

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/06

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/02/02

[补充]招股说明书

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2023/02/02

[补充]招股说明书

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2022/12/23

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership